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ÖZET
Oral prekanseröz lezyonlarda doku otofloresansı 
esaslı ışıkla değerlendirme yöntemi: Derleme
 
Amaç: Oral mukozanın otofloresans özellikleri oral prekanseröz 
lezyonların erken tanısında artan bir ilgiyle karşılanmaktadır. Son 
dönemde ışık esaslı oral kanser görüntülemeye yardımcı cihazlar 
ağız muayenesi ve tanıyı desteklemek amacıyla geliştirilmektedir. Bu 
cihazlar özel olarak tasarlanmış ışık kaynağıyla ağız muayenesinde 
mukozayı belirginleştirmek için otofloresans özelliğini kullanmakta-
dırlar. Bu bildirinin amacı ışık esaslı bir otofloresan izleme yönteminin 
oral premalign ve malign lezyonlarda potansiyel fayda ve risklerini 
ortaya koymaktır. 
Yöntem: Geniş literatür araştırması ve bu sistemlerden biriyle klinik 
tecrübe sistem değerlendirmesine olanak sağlamıştır. 
Bulgular: Bu yazıda prekanseröz ve kanserli lezyonların belirlenme-
sinde yardımcı izleme yöntemlerinden bir tanesi değerlendirilmiştir. 
Sistemin özellikleri ve dezavantajları değerlendirilmiş, klinisyenin 
dikkatine sunulmuştur. 
Sonuç: Günümüzdeki yenilikler malignite potansiyeli olan lezyonla-
rın erken tanısında yararlı olabilmektedir, ancak bunların tek başına 
diagnostik araçlar olmadığı, daha çok yardımcı araçlar oldukları 
düşünülerek dikkatle kullanılmaları gerekmektedir. Otofloresan kaybı 
mukozada displaziyi belirlemekte rol oynamakla beraber bu lezyon-
lar klinik bilgi ve deneyimle değerlendirilmelidir. 
Anahtar sözcükler: Otofloresans, velscope, prekanseröz lezyon
 
ABS TRACT
A light based screening method based on tissue 
autofluorescence for oral precancerous lesions: 
A review
Objective: Autofluorescence properties of oral mucosa has been 
gaining interest in the field of early diagnosis of oral precancerous 
lesions. To aid the oral cancer screening, light based systems have 
recently been developed in order to assist the oral examination 
and identification. These systems feature light sources with certain 
wavelength designed according to principles of tissue reflectance 
and autofluorescence to enhance the conventional oral examination. 
The purpose of this report is to address the potential benefits and 
potential risks of a light based autofluorescence screening method 
for potentially premalignant and malignant lesions. 
Methods: Extensive literature review and personal clinical experi-
ence with one of these technologies enabled the evaluation of the 
system. 
Results: This manuscript evaluated the use of one of the adjunctive 
screening methods to detect precancerous and cancerous lesions. 
The characteristics of the system were outlined, the limitations 
associated with autofluorescence screening were put forward for the 
clinician’s conderation. 
Conclusion: Recent technologies in the early detection of poten-
tially malignant lesions may be beneficial, however they should be 
used with cautious since they are only adjunctive methods. Loss 
of autofluorescence seems to play a role for identifying mucosal 
dysplasia but lesions should be evaluated with clinical knowledge 
and experience. 
Key words: Autofluorescence, velscope, precancerous lesion
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 INTRODUCTION
 Oral Cancer
 Oral cancer appears as the sixth most common 
malignancy worldwide, 90% of which consists of squamous 
cell carcinoma. It has been reported that the incidence rate 
of oral and pharyngeal cancers is decreasing overall 
however, the incidence rate of cancers of the tongue, 
oropharynx and tonsil is increasing. Early diagnosis of oral 
cancer is therefore crucial to improve the patient’s survival 
rate (1-3). However, because of the poor diagnosis of the 
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pre-malignant and malignant lesions, morbidity and 
mortality have not decreased over the past 50 years. In 
developed countries, the five-year survival was only 63% 
between 1999-2005. This poor prognosis is likely due to 
several factors. Oral cancer is frequently associated with the 
development of multiple primary tumors. The rate of 
second primary tumors in these patients, 3-7% per year, is 
higher than for any other malignancy (2-5).
 An invasive cancer may have different clinical signs; 
induration; persistent ulceration; tissue proliferation or 
destruction; red and white color; lack of mucosal mobility; 
progressive growth or enlargement of the affected site; 
pain or dysesthesia, paresthesia or loss of function; and 
cervical lymphadenopathy. Most oral squamous cell 
carcinomas exhibit one or more of these clinical signs, 
which often are identifiable on routine examination6.
 The terms ‘‘pre -cancer ’’,  ‘precursor lesions’, 
‘premalignant’,’intra epithelial neoplasia’ and ‘potentially 
malignant’ have been used in the international literature to 
broadly describe clinical presentations that may have a 
potential to become cancer. The World Health Organization 
(WHO) has periodically convened international workshops 
to redefine the term “precancer” and the various oral 
precancerous lesions. The most recent workshop, actually 
recommended the elimination of the term “precancer” and 
the use of the presumably more illuminating term 
“potentially malignant lesion” for oral lesions (7).
 Oral Examination
 Conventional oral examination (COE) for oral cancer 
involving visual inspection and palpation of oral lesions 
under illumination has been deficient. While COE may help 
to detect the oral lesions, it may not discover all potentially 
premalignant lesions (4). Since malignant and benign 
lesions may not be clinically evident, the clinician cannot 
predict the biological character of the lesions evaluating 
their physical features alone (4,8,18).
 In many cases, a biopsy is mandatory so that such 
lesions can be discarded. Histopathological examination 
and the classification of epithelial dysplasia still represent 
the gold standard in precancerous lesion risk evaluation.
 Oral Cancer Screening
 
 Lingen et al (4) defined the term as “Screening for 
disease has a precise definition and implies an ongoing, 
structured health care intervention designed to detect 
disease at an asymptomatic stage when its natural course 
can be readily interrupted if not cured. The important factor 
is that screening involves checking for the presence of 
disease in a person who is symptom-free”.
 There are some specific cancer screening programs 
which have been shown to reduce patient morbidity and 
mortality. Well-known Pap test for cervical cancer and 
mammography for breast cancer are used at any health 
care setting (4,8). 
 Early-stage lesions may be asymptomatic and resemble 
benign lesions whereas some alterations may not be readily 
evident in routine conventional white light oral examination.
 In order to detect oral pre-malignancy and malignancy, 
new technologies with new diagnostic tools for localizing 
or emphasizing dysplasia have been proposed (4,9-18). 
Adjunctive screening devices are on the market in order to 
aid the clinicians with the detection of early cancerous 
changes or for the assessment of the biological 
characteristics of mucosal lesions (4,8,9,17-19). 
 Oral Autofluorescence
 Autofluorescence technology has been already used in 
endoscopic instruments for bronchoscopy, esophageal 
examination, colonoscopy and skin evaluation18. In recent 
years, autofluorescence imaging has gained a growing 
interest in clinical practice for noninvasive imaging of the 
oral mucosa. With the help of different excitation wavelengths 
autofluorescence process occurs thanks to fluorochromes Figure 1: Tissue fluorescence and dysplastic progression.
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located in the epithelial cell lining and submucosa (e.g. 
collagen, elastin, keratin, oxidized flavine adenine 
dinucleotide (FAD), and nicotinamide adenine dinucleotide 
[NADH]). The normal intrinsic pattern of autofluorescence is 
modified by absorption and scattering (Figure 1). Light-
based imaging of the tissues has been popular and has 
claimed to detect early dysplastic changes. The philosophy 
of this concept is the autofluorescence properties of oral 
mucosa. The discovery and harnessing of fluorescent 
proteins, together with the subsequent biological and 
medical research have been significant enough to have 
culminated in a Nobel Prize in Chemistry (18). 
 There are some light-based oral cancer screening aids 
which have been developed to identify the precancerous 
and cancerous lesions as early as possible. These light-
based oral cancer screening aids use special light sources 
designed according to principles of tissue reflectance and 
tissue autofluorescence to enhance the oral examination 
process. Manufacturers of these devices claim that they 
may help the practitioner to visualize oral mucosal 
abnormalities that are not readily detectable with 
conventional operatory lighting, or that they can enhance 
the practitioner’s ability to specifically identify potentially 
malignant lesions (6). 
 
 A direct visual screening device based on
 autofluorescence: Visually Enhanced Lesion Scope
 (VELScope(R)) “Narrow-emission tissue fluorescence”
 
 VELscope (LED Dental, Burnaby, British Columbia, 
Canada) is an adjunctive device to aid the conventional oral 
examination in the identification of oral premalignancy 
which may not be apparent under conventional light (21). 
With the help of blue-light excitation (400–460 nm) 
provided by the unit, normal oral mucosa emits a pale 
green autofluorescence when viewed through the filter set 
incorporated within the hand-piece (Figure 2). Filtration is 
essential, as the intensity of the reflected blue-white light 
makes it otherwise impossible to visualize the narrow 
autofluorescent signal. The manufacturer of VELScope® 
indicates that abnormal mucosa exhibits decreased levels 
of autofluorescence appearing dark when compared with 
the surrounding tissue (6). On the other hand, loss of 
autofluorescence is not limited strictly to epithelial 
abnormalities and can be seen with prominent surface 
vascularity, including areas of inflammation, and melanin 
pigmentation (6,21). The device can be used during the 
surgery to identify the margins of the lesion for surgical 
excision (18,21). 
 Atypical or suspicious tissue exhibits decreased levels of 
normal autofluorescence and appears dark by comparison 
to the surrounding healthy tissue. An immature or dysplastic 
epithelial cell has much less NADH and FAD activity than a 
normal cell and so mucosal areas with such cells will not 
fluoresce, thereby appearing dark through the eyepiece 
(Figures 3a, 3b and 4a, 4b)(18,21,24).
 Benign lymphoid tissues, such as tonsils are almost lack 
Figure 2: VELscope device
Figure 3a: White light image of the angular mucosa of a 40-year-old 
heavy smoker patient with histopathologically confirmed dysplasia.
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of collagen and leukocytes may lack the autofluorescence 
molecules influenced by the wavelengths of the oral 
devices. They appear dark when viewed with the VELScope(R) 
(18). Bacterias using different fluorescent cytosol molecules 
give off a red, pink or orange fluorescence (Figures 5a and 
5b). Fungal microorganisms, such as candida, may fluoresce 
yellow or yellow/orange. 
 Many studies have assessed the sensitivity and specificity 
of autofluorescence screening for the detection of dysplastic 
and malignant lesions from normal oral mucosa (22, 23, 
25-35). Using histology as the gold standard, the device 
demonstrated varying sensitivity and specificity percentages.
 Lane et al. (25) showed a high sensitivity (98%) of 
VELscope(R). Awan et al. (33) determined 84,1% sensitivity 
and 15,3% specificity in distinguishing dysplastic lesions. 
Rana et al. (34) evaluated the sensitivity and specificity as 
100% and 74% respectively. Contrary to those findings, 
Farah et al. (29) indicated the sensitivity as 30% and 
specificity as 63%. Scheer et al. (30) showed that the 
sensitivity was 100% and the specificity was 80,8% whereas 
positive predictive value was 54,5% and negative predictive 
value was 100%. The system needs to be evaluated in more 
number of studies with larger groups.
 Despite its applicability, the system is expensive ranging 
from $4,000 to $7,000, and color interpretation is difficult, 
which could lead to an erroneous diagnosis. False positive 
screening results may happen due to lack of experience 
and lack of knowledge about oral mucosal diseases(36). 
 Other Light-based oral precancer screening devices
 Vizilite Plus with TBlue system (Zila Pharmaceuticals, 
Phoenix, Arizona,U.S.), Identafi (Trimira-Remicalm, 
Houston,TX, USA), Microlux/DL (AdDent Inc, Danbury, 
Connecticut) and Orascoptic DK (Orascoptic, Middleton, 
WI) are other light-based systems on the market.
Figure 3b: Fluorescence image showing areas with slightly deceased 
autofluorescence.
Figure 4a: White light image of the leukoplakia on the ventrum of 
the tongue.
Figure 4b: Fluorescence image showing minimum loss of 
fluorescence.
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 ViziLite imaging device has been on the market more 
than twelve years and it has been approved by FDA to use 
in the oral cavity and works with the emission of light from 
a chemical reaction between hydrogen peroxide and 
acetylsalicylic acid inside a capsule light stick. Thus, rinsing 
the mouth with 1% acetic acid solution for one minute is 
recommended when ViziLite / ViziLite Plus (ViziLite system 
combined with Toluidin Blue) are used. It is specificity is low 
as 14 % (18,19,31).
 Identafi, MicroLux DL and Orascoptic are other devices 
on the market claiming to have a capacity to enhance the 
identification of abnormal oral mucosa. The studies 
reflecting their clinical use, sensitivity and specificity are 
needed to assess their role in the detection of mucosal 
abnormalities (4,18,31). 
 A most preferred method for aiding the early detection 
of cancer is to have both low false negative rate and low 
false positive rate, however this has not seemed to be 
possible with the mentioned systems (4,31,35). 
 New Technologies 
 In order to detect the oral cancer earlier, new 
technologies seem to be promising. Some of them are; the 
use of saliva in oral cancer screening; the use of DNA 
aneuploidy analysis; loss-of-heterozygosity analysis; 
identification of bacterial markers in biofilms; identification 
of individual or multiple protein biomarkers revealed via 
tissue biopsies; the use of in vivo molecular probes and 
paints; and the use of other imaging modalities (6). 
 Chromosomal aberrations are key events in the initiation 
and progression of cancer. DNA-aneuploidy is considered 
to be a marker for the neoplastic transformation of cells. 
DNA-Image-Cytometry is used to detect the cytometric 
equivalent of chromosomal aneuploidy, which is called 
DNA-aneuploidy. This method gives information about the 
occurrence and number of abnormal stemlines, 
polyploidization of euploid or aneuploid stemlines, cell 
cycle fractions and occurrence of rare aneuploid cells with 
an abnormally high DNA content (11-15). Detection of loss 
of heterozygosity is another method in the detection of 
oral cancer. When the presence of heterozygosity at a 
genetic locus in an organism’s germline DNA, and the 
absence of heterozygosity at that locus in the cancer cells 
are detected, the loss of heterozygosity is determined. 
Recent studies have shown this method as promising (6,8).
 Saliva testing for specific mRNAs has been increasingly 
searched for the early diagnosis of oral cancer. Cell-free 
nucleic acids & proteins in saliva are used for the analysis. 
Molecular markers are mainly the changes in the cellular 
DNA, altered mRNA transcripts and altered protein markers. 
Figure 5a: Invasive squamous cell carcinoma on palatal mucosa
Figure 5b: With secondary infection and red glow from bacteria 
using different fluorescent cytosol molecules under fluorescent light
A light based screening method based on tissue autofluorescence for oral precancerous lesions: A review
112 Marmara Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi Cilt: 3, Sayı: 2, 2013 / Journal of Marmara University Institute of Health Sciences Volume: 3, Number: 2, 2013 - http://musbed.marmara.edu.tr
All the biomarkers were significantly altered in oral cancer 
and found to be useful as a supportive tool for diagnosis, 
prognosis and post-operative monitoring. These are; CycD1, 
K i67,  MMP-9,  OGG1,  Maspin,  Proangiogenic/
proinflammatory cytokines; IL-1, IL-6, IL-8, increased 
telomerase activity, presence of p53 autoantibodies, altered 
levels of reactive nitrogen species and antioxidants, HPV for 
HPV related cancer, DNA hypermethylation, salivary mRNA, 
transferrin and salivary biomarkers (Actin, myosin) (37-39). 
 Biofilms are bacterial communities that colonize the 
mouth in the form of dental plaque and recently their role 
in oral cancer can has been searched using with some 
techniques including DNA–DNA hybridization, 16S rRNA 
gene sequencing, denaturing gradient gel electrophoresis, 
terminal restriction fragment length polymorphism, 
denaturing high–performance liquid chromatography and 
pyrosequencing. New oral cancer screening tests based on 
salivary counts of different species of bacteria may help 
with screening compliance (37,38). The mentioned 
modalities will play important roles in future clinical 
practice.
 CONCLUSION
 Although oral mucosa screening using autofluorescence 
characteristics has been gaining interest over the few years, 
there is still a debate on its utility. Oral cancer screening is a 
part of a clinical oral examination that includes obtaining a 
patient history and an oral cancer risk assessment. 
Whenever an oral mucosal lesion is detected, re-evaluation 
in up to 14 days to see either persistence or healing of the 
lesion is essential. Only a definitive test examining cells or 
tissue can determine the biologic behavior of a lesion. 
When a definitive diagnosis is needed, a clinician should 
perform a surgical biopsy with subsequent specimen 
processing and histopathological examination.
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